Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Dow
Mallinckrodt
Baxter
AstraZeneca

Last Updated: January 30, 2023

Bromocriptine mesylate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What are the generic sources for bromocriptine mesylate and what is the scope of patent protection?

Bromocriptine mesylate is the generic ingredient in three branded drugs marketed by Lek Pharm, Mylan, Zydus Pharms Usa Inc, Validus Pharms, Padagis Us, Sandoz Inc, and Veroscience, and is included in eight NDAs. There are sixteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Bromocriptine mesylate has thirty-one patent family members in thirteen countries.

There are eight drug master file entries for bromocriptine mesylate. Seven suppliers are listed for this compound.

Summary for bromocriptine mesylate
Drug Prices for bromocriptine mesylate

See drug prices for bromocriptine mesylate

Recent Clinical Trials for bromocriptine mesylate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Andrew Moshfeghi, MD, MBAPhase 1/Phase 2
Case Western Reserve UniversityPhase 1/Phase 2
VeroSciencePhase 1

See all bromocriptine mesylate clinical trials

Pharmacology for bromocriptine mesylate
Medical Subject Heading (MeSH) Categories for bromocriptine mesylate

US Patents and Regulatory Information for bromocriptine mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for bromocriptine mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Veroscience CYCLOSET bromocriptine mesylate TABLET;ORAL 020866-001 May 5, 2009 See Plans and Pricing See Plans and Pricing
Validus Pharms PARLODEL bromocriptine mesylate CAPSULE;ORAL 017962-002 Mar 1, 1982 See Plans and Pricing See Plans and Pricing
Validus Pharms PARLODEL bromocriptine mesylate TABLET;ORAL 017962-001 Approved Prior to Jan 1, 1982 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Dow
Moodys
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.